📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 17:46
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Adline Chem Lab Reports Rs 4.01 Lakh Net Profit in Q1 FY27 Driven by Other Income
Adline Chem Lab reported a net profit of Rs 4.01 Lakh for the quarter ended June 30, 2026, marking a turnaround from a loss of Rs 5.13 Lakh in the year-ago period. However, the company continues to report zero revenue from operations, with the entire income of Rs 11.99 Lakh coming from 'Other Income'. Expenses for the quarter stood at Rs 8.80 Lakh, which notably included a Rs 1.06 Lakh penalty from the BSE for failing to appoint a Company Secretary. The company remains a micro-cap with a negative net worth of approximately Rs 2 Cr and no active core business revenue.
Confidence: HIGH
What changedThe company has turned profitable at the net level for the first time in over a year, though this is entirely due to non-operational income.
Why it mattersFor a company with negative net worth and zero revenue, non-operational income provides a temporary liquidity cushion, but the lack of a business model remains a critical risk.
Net Profit (Q1 FY27): Rs 4.01 LakhRevenue from Operations: Rs 0.00Other Income: Rs 11.99 LakhBSE Penalty: Rs 1.06 LakhPaid-up Equity Capital: Rs 585.00 Lakh
📅 Short termThe stock may see minor speculative interest due to the reported profit, but the lack of core business activity suggests limited upside.
📈 Long termThe long-term outlook remains weak unless the company successfully pivots or restarts its pharmaceutical operations and addresses its negative net worth.
⚠ Risk flags
- Zero operational revenue
- Negative net worth of Rs -2 Cr
- Regulatory non-compliance (BSE penalty)
- High finance costs relative to income
Key Highlights
Net Profit of Rs 4.01 Lakh in Q1 FY27 compared to a loss of Rs 5.13 Lakh in Q1 FY26
Revenue from operations remained at Rs 0.00 for the fifth consecutive quarter
Other Income of Rs 11.99 Lakh was the sole source of total income for the period
BSE imposed a penalty of Rs 1.06 Lakh for non-appointment of a Company Secretary
Finance costs stood at Rs 4.84 Lakh, representing over 50% of total quarterly expenses
👀 What to Watch
Investors should monitor if the company can restart its core pharmaceutical operations, as current profitability is purely non-operational. The regulatory penalty for non-compliance (Company Secretary) is a governance red flag to watch.
Adline Chem Lab Reports Q1 FY27 Net Profit of ₹4.01 Lakhs on Zero Operating Revenue
Adline Chem Lab reported a marginal net profit of ₹4.01 Lakhs for Q1 FY27, a turnaround from a loss of ₹9.26 Lakhs in the previous quarter. However, the company continues to report zero revenue from operations, with its total income of ₹11.99 Lakhs derived entirely from 'Other Income'. Total expenses decreased to ₹8.80 Lakhs from ₹11.72 Lakhs sequentially, though this includes a ₹1.06 Lakhs penalty for regulatory non-compliance. The company remains financially stressed with a negative net worth of ₹-2 Cr and no core business activity.
Confidence: HIGH
What changedThe company has shifted from a loss-making position to a marginal profit due to a spike in non-operating income, despite continued zero revenue from its main business.
Why it mattersThe lack of operating revenue and negative net worth (₹-2 Cr) indicate significant structural issues; the marginal profit does not yet signal a fundamental business recovery.
Net Profit (Q1 FY27): ₹4.01 LakhsRevenue from Operations: ₹0.00Other Income: ₹11.99 LakhsRegulatory Penalty (BSE): ₹1.06 LakhsNet Worth: ₹-2 Cr
📅 Short termThe stock may see speculative movement due to the reported profit, but the underlying lack of business activity remains a concern for the coming weeks.
📈 Long termLimited structural significance unless the company secures fresh capital or restarts its manufacturing/trading operations to generate sustainable revenue.
⚠ Risk flags
- Zero operating revenue
- Negative net worth
- Regulatory non-compliance (penalty for no Company Secretary)
- High finance costs relative to total expenses
Key Highlights
Net Profit of ₹4.01 Lakhs in Q1 FY27 compared to a loss of ₹9.26 Lakhs in Q4 FY26
Revenue from operations remained at ₹0.00, consistent with the previous four quarters
Other Income increased significantly to ₹11.99 Lakhs from ₹1.15 Lakhs in the preceding quarter
Finance costs of ₹4.84 Lakhs accounted for 55% of the total quarterly expenditure
BSE imposed a penalty of ₹1.06 Lakhs during the quarter for the non-appointment of a Company Secretary
👀 What to Watch
Investors should monitor whether the company can successfully restart its core pharmaceutical operations, as current profitability is entirely dependent on non-operating income. Watch for the appointment of a Company Secretary to resolve ongoing regulatory issues.
